TSPAN6 reinforces the malignant progression of glioblastoma via interacting with CDK5RAP3 and regulating STAT3 signaling pathway
View abstract on PubMed
Summary
This summary is machine-generated.Tetraspanin 6 (TSPAN6) promotes glioblastoma growth and metastasis by enhancing angiogenesis via exosomes. TSPAN6 may serve as a therapeutic target and prognostic biomarker for glioblastoma patients.
Area Of Science
- Oncology
- Molecular Biology
- Cell Biology
Background
- Glioblastoma is a highly malignant primary brain tumor with a poor prognosis.
- Exosomes mediate glioblastoma progression by regulating the tumor microenvironment (TME).
- Tetraspanin proteins (TSPANs) are key mediators of intercellular communication within the TME.
Purpose Of The Study
- To investigate the role of TSPAN6 in glioblastoma progression.
- To explore the potential of TSPAN6 as a prognostic biomarker and therapeutic target.
Main Methods
- Analysis of TSPAN6 expression levels in glioblastoma tissues.
- Assessment of TSPAN6's impact on glioblastoma cell proliferation, metastasis, and angiogenesis.
- Investigation of the interaction between TSPAN6, CDK5RAP3, and the STAT3 signaling pathway.
- Evaluation of exosome-mediated effects of TSPAN6 on vascular endothelial cell migration.
Main Results
- TSPAN6 is overexpressed in glioblastoma compared to normal tissues and correlates with shorter patient survival.
- TSPAN6 promotes glioblastoma cell proliferation and metastasis.
- TSPAN6 overexpression enhances vascular endothelial cell migration, suggesting a role in angiogenesis via exosomes.
- TSPAN6 interacts with CDK5RAP3 to regulate the STAT3 signaling pathway, contributing to glioblastoma malignancy and angiogenesis.
Conclusions
- TSPAN6 plays a significant role in glioblastoma progression, proliferation, metastasis, and angiogenesis.
- TSPAN6 influences glioblastoma through exosome-mediated communication and regulation of the STAT3 pathway.
- TSPAN6 represents a promising therapeutic target and prognostic biomarker for glioblastoma.
Related Concept Videos
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...

